top of page
Search

Steris (STE)

  • Writer: Abacus Research
    Abacus Research
  • Nov 26, 2019
  • 1 min read

Steris is a high quality sterilisation business, with ~6.5% sustainable organic growth due to pricing power and volume growth. Regarding business positioning, there is little not to like. 


We would argue that Steris has all the markings of compounder, and has got to the point where the balance sheet has delevered and synergies have run out, therefore a deal or share buy backs should be on the cards. 


Ethylene Oxide is causing a lot of concern, however we are unconcerned by the EPA's focus as we do not see Ethylene Oxide as a risk for Steris.  Unfortunately, as for many other defensives, we find the risk reward balanced. 


Potential Upside: $174(+16%)

Sensible Downside: $122(-20%)


 
 
 

Recent Posts

See All
RYAN / Insurance Cycle

Ryan (RYAN) is a typical hard market beneficiary, that is going through an organic growth reset. Are we there yet in terms of the reset- probably not. Timing the bottom of a cyclical market is hard. N

 
 
 
Nebius & DigitalOcean: Inference Efficiency

(NBIS, DOCN) 1. The Core AI Thesis At the core of all AI theses there are two beliefs: Demand for intelligence is ~infinite — this still seems to be true, at leas there is no data to the contrary. Com

 
 
 
SEDG, ENPH, NVTS: Plays on 800V

Everybody knows about the 800V conversion that is coming. NVDA etc have released the specs. There are many parts to that ecosystem change. Most of them are not ‘free options’ whereas SEDG and ENPH mos

 
 
 

Comments

bottom of page